开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2024-02-15 1243aaabm66暂无昵称来自澳大利亚

审稿速度:2.0 | 投稿命中率:50.0
经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。

101 0

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2024-01-17 Doctor.L 来自辽宁省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制
经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。

98 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2023-12-13 1488cf0fm85暂无昵称来自北京

2天送审，审稿了1个月没反应呢

100 0

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2023-05-22 ms3000001625045669 来自陕西省

偏重的研究方向：肝病;临床
经验分享：投了3天没有动静

90 0

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2023-02-15 ms4000000947619634 来自香港

今年能上10分吗，去年9.9分

110 0

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2023-01-18 showtest 来自上海

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：非酒精性脂肪肝;肝病;肝癌
经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。
JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 .

232 0

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2023-01-17 123木头人... 来自安徽省

J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。

194 0

[GetPortalCommentsPageByObjectIdResponse(id=2187476, encodeId=3d4d218e476f4, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：刚中了一篇jhep reports。这篇文章本来觉得投Hepatology应该没问题的，没想到编辑说需要再加张图的数据才给送外审，就直接投的jhep，直接送外审了，修稿阶段还是把hepa要求的那张大图补了。比较有潜力吧，年文章100篇，审稿人非常非常专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Thu Feb 15 21:40:38 CST 2024, time=2024-02-15, status=1, ipAttribution=澳大利亚), GetPortalCommentsPageByObjectIdResponse(id=2182265, encodeId=fbcf2182265ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌的基础临床转化;肝癌分子发病机制 经验分享：这是一本潜力巨大、非常优秀的期刊，出身名门。个人而言，从投稿到接收，基本上6个月，中间补了很多实验和验证，只能说非常具有不容易，很有挑战性，也期待优秀的同行用丰硕的成果多多挑战该期刊，肯定会越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50d12072527, createdName=Doctor.L, createdTime=Wed Jan 17 19:07:14 CST 2024, time=2024-01-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174661, encodeId=ff4a21e46615b, content=2天送审，审稿了1个月没反应呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7e75312121, createdName=1488cf0fm85暂无昵称, createdTime=Wed Dec 13 10:10:15 CST 2023, time=2023-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138373, encodeId=208321383e3cb, content=偏重的研究方向：肝病;临床 经验分享：投了3天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ff85727160, createdName=ms3000001625045669, createdTime=Mon May 22 13:17:03 CST 2023, time=2023-05-22, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2114838, encodeId=f688211483835, content=今年能上10分吗，去年9.9分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Wed Feb 15 23:57:23 CST 2023, time=2023-02-15, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2110672, encodeId=798c21106e292, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：非酒精性脂肪肝;肝病;肝癌 经验分享：这是J HEP，首个影响因子就10分，虽然是著名刊物的子刊，同样是EASL的官方期刊，但是并不容易投的，要求仍然是很高的。 JHEP Reports 是备受推崇的 Journal of Hepatology 的开放获取姊妹刊。它发表与肝病学领域的基础、转化和临床研究有关的原创论文、评论和致编辑的信件。 JHEP Reports 是一份创新期刊，发表有关全球肝病学问题的文章，特别关注临床试验、新诊断学、精准医学和治疗学、细胞和分子研究、新陈代谢、癌症、微生物组、系统生物学、流行病学以及生物技术进步和设备 ., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 18 01:36:57 CST 2023, time=2023-01-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110652, encodeId=07382110652fe, content=J HEP的子刊，首个IF就是接近10分。对文章质量要求很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/84464850e74a4249b97dcfdb867d8f4d/6ebad1e162c744459baa5140987d5fdf.jpg, createdBy=22ee5323538, createdName=123木头人..., createdTime=Tue Jan 17 23:13:26 CST 2023, time=2023-01-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2100070, encodeId=14a321000e09d, content=试试投稿，感觉不会很容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71d32361211, createdName=122d0536m11(暂无昵称), createdTime=Sat Nov 12 13:10:55 CST 2022, time=2022-11-12, status=1, ipAttribution=)]

2022-11-12 122d0536m11(暂无昵称)

试试投稿，感觉不会很容易

186 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务